BIONTECH SE - AMERICAN DEPOSITARY SHARES

BioNTech Announces Establishment of Interdisciplinary mRNA Excellence Center to Conduct Research Jointly with Scientists from Weizmann Institute of Science in Israel

01 мар 2023 07:00:00 Источник Nasdaq GlobeNewswire

BioNTech Strengthens Manufacturing Capabilities with First In-House Plasmid DNA Manufacturing Facility

02 фев 2023 05:45:00 Источник Nasdaq GlobeNewswire

BioNTech to Acquire InstaDeep to Strengthen Pioneering Position in the Field of AI-powered Drug Discovery, Design and Development

10 янв 2023 06:15:00 Источник Nasdaq GlobeNewswire

BioNTech Announces Strategic Partnership with UK Government to Provide up to 10,000 Patients with Personalized mRNA Cancer Immunotherapies by 2030

05 янв 2023 18:01:00 Источник Nasdaq GlobeNewswire

BioNTech to Present at the 41st Annual J.P. Morgan Healthcare Conference

28 дек 2022 05:45:00 Источник Nasdaq GlobeNewswire

BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165

23 дек 2022 02:00:00 Источник Nasdaq GlobeNewswire

BioNTech and Fosun Pharma Provide COVID-19 Vaccine Doses For Vaccination of German Expatriates in China

22 дек 2022 05:00:00 Источник Nasdaq GlobeNewswire

Update on First BioNTainer for African-based mRNA Manufacturing Facility

21 дек 2022 07:45:00 Источник Nasdaq GlobeNewswire

BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163

21 дек 2022 05:45:00 Источник Nasdaq GlobeNewswire

Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza

09 дек 2022 05:45:00 Источник Nasdaq GlobeNewswire

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years

08 дек 2022 09:39:34 Источник Nasdaq GlobeNewswire

BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates

30 ноя 2022 00:02:35 Источник Nasdaq GlobeNewswire

Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages

18 ноя 2022 05:45:00 Источник Nasdaq GlobeNewswire

Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection

16 ноя 2022 17:30:00 Источник Nasdaq GlobeNewswire

BioNTech Expands Global Footprint by Acquiring GMP Manufacturing Site to Establish First mRNA Facility in Singapore

13 ноя 2022 19:30:00 Источник Nasdaq GlobeNewswire

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union

10 ноя 2022 08:45:00 Источник Nasdaq GlobeNewswire

BioNTech Announces Third Quarter 2022 Financial Results and Corporate Update

07 ноя 2022 05:00:00 Источник Nasdaq GlobeNewswire

Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine

04 ноя 2022 05:48:48 Источник Nasdaq GlobeNewswire

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age

12 окт 2022 09:30:00 Источник Nasdaq GlobeNewswire

Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron

25 июн 2022 09:02:16 Источник Nasdaq GlobeNewswire